Studies have found that SMARCA4 combined with TP53 mutation may indicate a specific tumor subtype or a more aggressive tumor phenotype (7), which is helpful to classify and diagnose tumors more accurately and provide a basis for subsequent precise treatment. This evidence concerns the gene SMARCA4 and neoplasm.